Anti-CD22 and anti-CD79B antibody drug ...
Document type :
Article dans une revue scientifique
DOI :
PMID :
Permalink :
Title :
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes
Author(s) :
Pfeifer, M [Auteur]
Zheng, B [Auteur]
Erdmann, T [Auteur]
Koeppen, H [Auteur]
Mccord, R [Auteur]
Grau, M [Auteur]
Staiger, A [Auteur]
Chai, A [Auteur]
Sandmann, T [Auteur]
Madle, H [Auteur]
Doerken, B [Auteur]
Chu, Yu-Waye [Auteur]
Chen, AI [Auteur]
Lebovic, D [Auteur]
Salles, Gilles [Auteur]
Czuczman M., S [Auteur]
Palanca-Wessels, Maria Corinna [Auteur]
Press, Oliver [Auteur]
Advani, Ranjana [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Cheson, BD [Auteur]
Lenz, P [Auteur]
Ott, G [Auteur]
Polson A., G [Auteur]
Mundt K., E [Auteur]
Lenz, Georg [Auteur]
Zheng, B [Auteur]
Erdmann, T [Auteur]
Koeppen, H [Auteur]
Mccord, R [Auteur]
Grau, M [Auteur]
Staiger, A [Auteur]
Chai, A [Auteur]
Sandmann, T [Auteur]
Madle, H [Auteur]
Doerken, B [Auteur]
Chu, Yu-Waye [Auteur]
Chen, AI [Auteur]
Lebovic, D [Auteur]
Salles, Gilles [Auteur]
Czuczman M., S [Auteur]
Palanca-Wessels, Maria Corinna [Auteur]
Press, Oliver [Auteur]
Advani, Ranjana [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Cheson, BD [Auteur]
Lenz, P [Auteur]
Ott, G [Auteur]
Polson A., G [Auteur]
Mundt K., E [Auteur]
Lenz, Georg [Auteur]
Journal title :
Leukemia
Abbreviated title :
Leukemia
Volume number :
29
Pages :
1578-1586
Publication date :
2015
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Antibody drug conjugates (ADCs), in which cytotoxic drugs are linked to antibodies targeting antigens on tumor cells, represent promising novel agents for the treatment of malignant lymphomas. Pinatuzumab vedotin is an ...
Show more >Antibody drug conjugates (ADCs), in which cytotoxic drugs are linked to antibodies targeting antigens on tumor cells, represent promising novel agents for the treatment of malignant lymphomas. Pinatuzumab vedotin is an anti-CD22 ADC and polatuzumab vedotin an anti-CD79B ADC that are both linked to the microtubule-disrupting agent monomethyl auristatin E (MMAE). In the present study, we analyzed the activity of these agents in different molecular subtypes of diffuse large B-cell lymphoma (DLBCL) both in vitro and in early clinical trials. Both anti-CD22-MMAE and anti-CD79B-MMAE were highly active and induced cell death in the vast majority of activated B-cell-like (ABC) and germinal center B-cell-like (GCB) DLBCL cell lines. Similarly, both agents induced cytotoxicity in models with and without mutations in the signaling molecule CD79B. In line with these observations, relapsed and refractory DLBCL patients of both subtypes responded to these agents. Importantly, a strong correlation between CD22 and CD79B expression in vitro and in vivo was not detectable, indicating that patients should not be excluded from anti-CD22-MMAE or anti-CD79B-MMAE treatment because of low target expression. In summary, these studies suggest that pinatuzumab vedotin and polatuzumab vedotin are active agents for the treatment of patients with different subtypes of DLBCL.Show less >
Show more >Antibody drug conjugates (ADCs), in which cytotoxic drugs are linked to antibodies targeting antigens on tumor cells, represent promising novel agents for the treatment of malignant lymphomas. Pinatuzumab vedotin is an anti-CD22 ADC and polatuzumab vedotin an anti-CD79B ADC that are both linked to the microtubule-disrupting agent monomethyl auristatin E (MMAE). In the present study, we analyzed the activity of these agents in different molecular subtypes of diffuse large B-cell lymphoma (DLBCL) both in vitro and in early clinical trials. Both anti-CD22-MMAE and anti-CD79B-MMAE were highly active and induced cell death in the vast majority of activated B-cell-like (ABC) and germinal center B-cell-like (GCB) DLBCL cell lines. Similarly, both agents induced cytotoxicity in models with and without mutations in the signaling molecule CD79B. In line with these observations, relapsed and refractory DLBCL patients of both subtypes responded to these agents. Importantly, a strong correlation between CD22 and CD79B expression in vitro and in vivo was not detectable, indicating that patients should not be excluded from anti-CD22-MMAE or anti-CD79B-MMAE treatment because of low target expression. In summary, these studies suggest that pinatuzumab vedotin and polatuzumab vedotin are active agents for the treatment of patients with different subtypes of DLBCL.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Université de Lille
CHU Lille
CHU Lille
Collections :
Research team(s) :
Innovation/évaluation des médicaments injectables
Submission date :
2019-02-26T17:07:41Z